On Monday, the U.S. Food and Drug Administration lifted the two-year clinical hold on GH Research’s Investigational New Drug (IND) application for GH001, the company’s inhalable bufotenin candidate for treatment-resistant depression (TRD). The hold, imposed in September 2023 due to insufficient safety data, has been removed after GH Research provided additional nonclinical toxicology studies and manufacturing information. Company CEO Dr. Velichka Valcheva stated that FDA clearance ‘‘positions us to advance GH001 as a potential ultra-rapid and durable treatment option for TRD patients’’ and confirmed plans to initiate a global pivotal Phase 3 program in 2026 following alignment discussions with agency reviewers. GH Research’s Phase 2b trial data from February 2025 showed that a single inhaled dose of GH001 produced a mean reduction of 15.2 points from baseline on the Montgomery-Åsberg Depression Rating Scale (MADRS) by Day 8, compared with a 0.3-point increase in the placebo cohort (difference of 15.5 points, p<0.0001). Additionally, 73% of patients maintained remission at six months with intermittent, clinic-based dosing, highlighting both rapid onset and sustained effect. External expert Michael E. Thase, MD, remarked that these results ‘‘have the potential to be practice-changing for patients with treatment-resistant depression.’" As of the most recent financial report, GH Research holds approximately $294 million in cash and cash equivalents. At the current quarterly burn rate of roughly $12 million, management projects a cash runway exceeding five years, cushioning the company through pivotal study execution and regulatory interactions. The disciplined cost structure, with research and development expenses accounting for 70% of total operating costs in the last fiscal year, underpins the firm’s ability to fund late-stage development without near-term equity dilution. GH Research plans to meet with the FDA during the first half of 2026 to finalize the design of its pivotal Phase 3 program for GH001. The proposed global trial is expected to enroll 300 to 400 TRD patients, with primary endpoints focused on MADRS change at Day 8 and sustained remission at three months. Concurrently, the company is advancing manufacturing scale-up for its proprietary inhalation device and securing partnerships for commercial distribution, with topline data anticipated in late 2027.